Skip to main content
All Posts By

admin

relevant-health-logo

A new health tech accelerator rises in Maryland – MedCity NewsMedCity News

By Uncategorized

relevant-health-logo

A new health technology accelerator is looking for applicants for its five month program.It is the latest in a steady growth of organizations helping entrepreneurs navigate the long sales cycle and other unique challenges healthcare industry startups face.

Relevant Health, based in Rockville, Maryland, was formed through a partnership between BioHealth Innovation, Montgomery County’s Economic Development department and Product Savvy, which will run the day-to-day operations.

Read More
barco-logo

$10M Open Works incubator for artists, makers slated for Station North – Baltimore Business Journal

By News Archive

barco-logo

When Open Works makes its debut in the Station North Arts and Entertainment District next year, Will Holman hopes it will become just the kind of place where he can set up shop. An architect by training and furniture maker, Holman is also the project director for Open Works, a $10 million incubator Baltimore Arts Realty Corp. is developing in a warehouse across from Greenmount Cemetery.

Read More
pieris-pharmaceuticals-inc-logo

PIERIS PHARMACEUTICALS COMPLETES DOSING OF HEALTHY VOLUNTEERS IN PHASE I CLINICAL TRIAL FOR ANTICALIN PROGRAM IN ANEMIA

By News Archive

pieris-pharmaceuticals-inc-logo

Pieris Pharmaceuticals, Inc. (OTCQB: PIRS), a biotechnology company advancing its proprietary Anticalin® biotherapeutic technologies, announced today the completion of enrollment of healthy subjects in a blinded, placebo-controlled Phase I clinical trial for the Company’s PRS-080 program, a hepcidin antagonist to treat anemia. This study was conducted at a single site in Germany.

Read More

154th Edition – June 10, 2015

By BHI Weekly Newsletter Archives

new-eir-rotator

BHI EXPANDS ENTREPRENEUR-IN-RESIDENCE (EIR) PROGRAM

By Uncategorized

−Drs. Steve Wolpe and Ethel Rubin Named EIRs for National Institutes of Health; Dr. Albine Martin to Serve as EIR Working with Johns Hopkins University and Maryland-Based Health-Technology Companies

−BHI Continues Search for Neurology and Neuroscience Experts to Fill Roles of EIRS for the National Institute of Neurological Disorders and Stroke (NINDS)

new-eir-rotatorROCKVILLE AND BALTIMORE, MARYLAND, June 8, 2015 – BioHealth Innovation, Inc. (BHI) announced today the hiring of three new entrepreneurs-in-residence (EIRs): two for the NIH and one to work with Johns Hopkins University (JHU) and Maryland-based health-technology companies. Additionally, BHI is actively recruiting neuroscience and neurology experts for EIR positions within the NIH’s National Institute of Neurological Disorders and Stroke (NINDS).

Read More
biomaryland-logo

Visit BioMaryland (Booth #301) at the BIO Intl Conf in Philly Next Week!

By News Archive

biomaryland-logo

Hundreds of people from more than 140 life sciences organizations based in Maryland are traveling to the BIO International annual conference taking place next week, June 15th-18th, in Philadelphia.

Stop by our Booth (#301), enjoy a cup of espresso, meet key industry leaders, and learn more about the many resources and experts available in Maryland to help you grow your business!

Read More
Clarus-Ventures-logo

Good Times Roll on for Biotech VCs As Clarus Bags New $500M Fund – Xconomy

By News Archive

Clarus-Ventures-logo

Take a poll of most of biotech’s venture capitalists—the ones that survived the financial crash, anyway—and you might find that just about all of them have reloaded with new funds over the past few years. Today, you can add Clarus Ventures to the list.

Clarus—a VC firm with offices in the bi-coastal biotech hotbeds of Cambridge, MA, and South San Francisco, CA—has raised its third fund, a $500 million haul called Clarus Lifesciences III LP that’ll it’ll use to invest in both early and mature drug developers.

Read More
symbiomix-logo

Symbiomix Therapeutics Doses First Patient in Confirmatory Phase 3 Pivotal Study of Lead Drug Candidate SYM-1219 for Bacterial Vaginosis – kcentv.com – KCEN HD – Waco, Temple, and Killeen

By News Archive

symbiomix-logo

Symbiomix Therapeutics today announced the dosing of the first patient in a Phase 3 clinical trial, the second of two planned pivotal trials for its lead drug candidate SYM-1219 for the treatment of bacterial vaginosis (BV). Symbiomix previously announced that it plans to submit the multi-center, randomized Phase 2 trial completed last year as one of two pivotal trials required for a New Drug Application (NDA) filing. This Phase 3 trial is the second pivotal study to support an NDA submission for BV. SYM-1219 is a novel drug candidate that contains secnidazole, an antibiotic with favorable pharmacokinetics (PK) allowing for single-dose oral therapy in a condition that is marked by high recurrence rates and low adherence to the current recommended treatment.

Read More

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.